CRISPR Therapeutics Reaches Analyst Target Price
June 21, 2018 at 07:48 AM EDT
In recent trading, shares of CRISPR Therapeutics AG (CRSP) have crossed above the average analyst 12-month target price of $63.92, changing hands for $65.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..